Glycoprotein VI
GPVI
Glycoprotein VI (GPVI) is a membrane glycoprotein unique to platelets and has been identified as a physiological receptor for collagen. Damage to a vessel wall exposes the subendothelial component collagen to platelets in the blood flow. Interaction of platelets with collagen via the receptor GPVI results in platelet activation and adhesion--the processes that are essential for thrombus formation. On the platelet surface, GPVI is present as a complex with the homodimeric Fc receptor y-chain (FcRgamma with a possible stoichiometry of two GPVI molecules and one FcRgamma dimer). When collagen binds to GPVI, a platelet activation cascade is initiated by tyrosine phosphorylation of the immunoreceptor tyrosine-based activation motif of FcRgamma and this phosphorylation induces the formation of a large complex composed from many signal-transducing proteins. In flow adhesion experiments that closely approximate physiological conditions, GPVI is essential for the formation of large platelet aggregates on collagen.
All Product Categories
-
Glycoprotein VI Related Products (20)
-
Antibodies (1)
- 1
-
Codrituzumab
0 ImagesSynonyms: GC33; RO5137382Codrituzumab (GC33) is a humanized monoclonal antibody targeting human GPC3 (glypican-3), with high affinity (Kd of 0.673 nM). GPC3 is an oncofetal protein expressed on the cell surface of hepatocellular carcinoma (HCC). Codrituzumab induces antibody-dependent cellular cytotoxicity (ADCC) and inhibits tumor growth.
-
ACT017
0 ImagesACT017 is a Fab fragment of humanized anti-GPVI monoclonal antibody. ACT017 inhibits collagen-induced platelet aggregation. ACT017 has the potential for the research of acute ischemic stroke.
-
GPC3 targeting peptide 1 TFA
0 ImagesCat. No.: HY-P10888APurity: 99.40%GPC3 targeting peptide 1 TFA is a GPC3 targeting peptide, with a Kd value of 0.23 nM.
-
Anti-GPC3 Antibody (YP7)
0 ImagesCat. No.: HY-P990840
-
DOTA-GPC3 targeting peptide 2
0 ImagesDOTA-GPC3 targeting peptide 2 (Sequence 30) is a RDC peptide targeting GPC3, with Kd of 0.3 nM. DOTA-GPC3 targeting peptide 2 is composed of DOTA and GPC3 targeting peptide 2. DOTA-GPC3 targeting peptide 2 can be labeled with radioactive elements.
-
ZW-251 Antibody
0 ImagesCat. No.: HY-P992514ZW-251 Antibody is a humanized IgG1 antibody targeting GPC3, it can be used to synthesize the ADC ZW251.
-
CAT-07
0 ImagesCat. No.: HY-P992011CAT-07 is an anti-human GPC3/Glypican 3 antibody. CAT-07 can be used for the research of cancer, such as hepatocellular carcinoma.
-
SAR444200
0 ImagesCat. No.: HY-P992457SAR444200 is a nanobody targeting GPC3 (glypican-3) and TCRαβ (T-cell receptor αβ). The KD of SAR444200 for human GPC3 is 0.023 nM, and its KD for human TCRαβ is 5.2 nM. SAR444200 mediates T cell-dependent cytotoxicity, and exhibits high selectivity and killing activity against GPC3-positive tumor cells. SAR444200 binds to GPC3 in a dual-epitope manner, and binds to TCRαβ via its N-terminal nanobody, forming an artificial immunological synapse between T cells and tumor cells. SAR444200 can be used in studies of GPC3+ solid tumors, including liver cancer, lung squamous cell carcinoma and melanoma.
-
(S)-S007-1558
0 ImagesSynonyms: GPVI antagonist 1(S)-S007-1558 (compound 5) is a glycoprotein VI (GPVI) platelet receptor antagonist. (S)-S007-1558 inhibits collagen-induced platelet aggregation with an IC50 of 25.3 μM.
-
Anti-pan-Glypican Antibody (HS20)
0 ImagesCat. No.: HY-P990841Purity: 99.44%Anti-pan-Glypican Antibody (HS20) is a kind of human IgG1 κ human antibody, targeting to human pan-Glypican. Anti-pan-Glypican Antibody (HS20) can neutralize the heparan sulfate (HS) chains on GPC3 thereby disrupting the Wnt3a-GPC3 interactions leading to blockade of the Wnt3a/β-catenin signaling. Anti-pan-Glypican Antibody (HS20) can be used for the research of cancer, such as hepatocellular carcinoma (HCC).
-
Anti-GPC-2 Antibody (CT3)
0 ImagesCat. No.: HY-P990842
-
Batifiban TFA
0 ImagesCat. No.: HY-125053APurity: 99.70%Batifiban TFA, a cyclic peptide, is an antagonist of platelet glycoprotein GPⅡb/Ⅲa and inhibits platelet aggregation. Batifiban blocks the binding of circulating vitronectin to integrin ανβ3.
-
Convulxin
0 ImagesCat. No.: HY-117123CAS No.: 37206-04-5Convulxin is a toxin found in a tropical rattlesnake. Convulxin stimulates platelet aggregation, and clusters GPVI to trigger Src family kinase activation, Fc receptor γ chain phosphorylation, and p72SYK signaling. Convulxin interacts with Dectin-2 to induce IL-10 production, activates monocytes to generate ROS and NLRP3 inflammasome-mediated IL-1β secretion, and induces mitochondrial ROS. Convulxin causes transient arterial blood pressure changes in dogs. Convulxin can be used for research related to coagulation.
-
10P3Me
0 ImagesCat. No.: HY-P1161810P3Me is a Glypican-3 (GPC3)-targeting probe with a Ka of 93.8 nM for the human target. 10P3Me exhibits high binding affinity to GPC3, targets GPC3-positive cells, and serves as an agent for PET imaging. 10P3Me selectively accumulates in GPC3-positive tumor tissues, including subcutaneous xenograft models and orthotopic HepG2-LUC liver cancer models, to achieve precise localization of lesions.
-
GPVI antagonist 3
0 ImagesCat. No.: HY-115912CAS No.: 901654-94-2GPVI antagonist 3 (Compound 2) is a potential antagonist of Glycoprotein VI (GPVI). IC50 values of GPVI antagonist 3 are, respectively, 1.01 μM for collagen, 1.92 μM for CRP, 7.24 μM for convulxin and 51.74 μM for thrombin. Glycoprotein VI (GPVI) is a platelet major collagen receptor and a target for potent and safe antithrombotic research. GPVI antagonist 3 is a promising antiplatelet agent.
-
pep-10L peptide
0 ImagesCat. No.: HY-P10949CAS No.: 1159846-95-3Pep-10L peptide is a glycoprotein VI (GPVI) antagonist with Ki values of 180, 225, and 179 μM for CPR, GPO-1, and Type 1 collagen, respectively. Pep-10L peptide has anti-thrombotic effects.
-
GPVI antagonist 2
0 ImagesGPVI antagonist 2 (Compound 1) is a potential antagonist of Glycoprotein VI (GPVI). IC50 values of GPVI antagonist 2 are, respectively, 0.35 μM for collagen, 0.80 μM for CRP, 195.2 μM for convulxin and 81.38 μM for thrombin. Glycoprotein VI (GPVI) is a platelet major collagen receptor and a target for potent and safe antithrombotic research. GPVI antagonist 2 is a promising antiplatelet agent.
-
DMP 728 methanesulfonate
0 ImagesCat. No.: HY-125615CAS No.: 155158-97-7DMP 728 methanesulfonate is a platelet glycoprotein (GP) IIb/IIIa receptor antagonist. DMP 728 methanesulfonate shows dose-dependent antiplatelet and antithrombotic effects. DMP 728 methanesulfonate can be used in the study of effective antithrombotic agents in thromboembolic diseases of coronary and peripheral arteries.
-
GPC3 targeting peptide 1
0 ImagesCat. No.: HY-P10888CAS No.: 3066113-41-2GPC3 targeting peptide 1 is a GPC3 targeting peptide, with a Kd value of 0.23 nM.
- 1
